Track market-moving stories before they get noisy

37.98K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 2, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

On July 29, 2026, the Federal Trade Commission (“FTC”), the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection sued Hims & Hers in the Northern District of California. According to the FTC, the action alleges that Hims & Hers fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is “right for them.” The FTC also alleges that the company has made it difficult for consumers to cancel subscriptions and misled consumers about keeping their health information private. The FTC alleges that Hims shared consumers’ health information with Meta, Snap and other third parties.

Following this news, the price of Hims & Hers stock fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.

Based on the FTC allegations, the complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts to investors, including that (1) the Company shared consumers’ health information with third-party advertising platforms; (2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is “right for them;” (3) the foregoing conduct subjected the Company to regulatory scrutiny; (4) as a result of the foregoing, the Company was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

CLICK HERE TO LEARN MORE

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
[email protected]

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/hims-hers-health-inc-class-action-investigation-learn-more-now/

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Hims class action, go to https://rosenlegal.com/cases/hims-hers-health-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Hims shared consumers' health information with third-party advertising platforms; (2) Hims charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected Hims to regulatory scrutiny; (4) as a result of the foregoing, Hims was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, defendants' positive statements about Hims' business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Hims class action, go to https://rosenlegal.com/cases/hims-hers-health-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320625

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Key Takeaways NVR's Q3 earnings fell 20.4% year over year to $89.45 per share, missing estimates by 15.7%.Homebuilding gross margin fell 270 basis points to 18.3% amid higher lot costs and pricing pressure.Backlog units rose 10% to 10,121, while Mortgage Banking income before taxes increased 7% to $35 million.
NVR, Inc. (NVR - Free Report) reported third-quarter 2026 results, with earnings and Homebuilding revenues missing the Zacks Consensus Estimate. Both metrics also declined on a year-over-year basis.

The quarter reflected fewer settlements, softer pricing and margin pressure amid affordability challenges and weak consumer sentiment. New orders declined and cancellations increased, but backlog units rose 10% year over year.

Following the results, NVR stock jumped 3.6% during yesterday’s trading hours, potentially supported by backlog growth, improved Mortgage Banking profitability and continued share repurchases despite weaker earnings.

Inside NVR’s Q3 HeadlinesThe company reported earnings of $89.45 per share, down 20.4% year over year and missing the Zacks Consensus Estimate of $106.11 by 15.7%.

Homebuilding revenues of $2.35 billion also missed the consensus mark of $2.60 billion by 9.8%. Revenues declined 8.2% year over year from $2.56 billion, reflecting lower settlement volumes and a decrease in the average settlement price.

Consolidated revenues (Homebuilding & Mortgage Banking fees combined) amounted to $2.40 billion, down 7.9% on a year-over-year basis.

NVR Faces Lower Settlements and Pricing PressureSettlements fell 7% to 5,268 units from 5,639 units, limiting revenue generation during the quarter. The Mid Atlantic region recorded 1,786 settlements compared with 2,008 a year ago, while Mid East settlements declined to 1,090 from 1,200.

South East settlements decreased to 1,915 units from 2,011, while North East settlements increased to 477 units from 420. The average settlement price declined 2% year over year to $445,900, adding to the pressure from fewer closings.

NVR Sees Homebuilding Margin CompressionHomebuilding gross margin contracted to 18.3% from 21% a year ago, reflecting a 270-basis-point decline. Profitability was pressured by higher lot costs, continued affordability challenges and weak consumer sentiment, which contributed to increased pricing pressure. Our estimate for the metric was 19.9%.

The quarter also included approximately $24.8 million of contract land deposit impairments. Consequently, Homebuilding income before taxes declined 27% year over year to $299.7 million from $411.4 million.

NVR's Mortgage Banking Profitability ImprovesMortgage banking fees increased to $53.1 million from $49.2 million in the prior-year quarter. However, mortgage closed loan production declined 10% year over year to $1.38 billion from $1.54 billion, reflecting lower financing activity.

Despite weaker loan production, Mortgage Banking income before taxes increased 7% to $35 million from $32.7 million. The capture rate, representing the percentage of NVR homebuyers using the company's mortgage services, decreased to 85% from 86%.

NVR Faces Slower New Order ActivityNew orders, net of cancellations, declined 7% year over year to 4,391 units from 4,735. Mid Atlantic orders decreased to 1,641 units from 1,714, while North East orders fell to 232 from 433.

Mid East orders declined to 891 units from 931, while South East orders decreased to 1,627 from 1,657. The average sales price of new orders fell 5% to $442,100 from $464,800.

The cancellation rate increased to 21% from 19.4%, indicating that a greater proportion of signed contracts failed to convert into firm orders during the quarter.

NVR's Backlog Expands Despite Softer PricingBacklog totaled 10,121 units as of Sept. 30, 2026, up 10% from 9,165 units a year earlier. The dollar value of backlog increased 4% to $4.59 billion, reflecting a larger volume of homes awaiting settlement.

However, the average backlog price declined to $453,000 from $479,500. Average active communities increased to 454 from 450, slightly expanding the company's selling footprint despite softer order activity.

NVR Maintains Liquidity and Continues BuybacksHomebuilding cash and cash equivalents were $1.09 billion as of Sept. 30, 2026, compared with $1.88 billion at the end of 2025. Homebuilding inventory increased to $2.37 billion from $1.72 billion during the same period. Mortgage Banking cash and cash equivalents were $34.1 million compared with $32.6 million at year-end.

NVR repurchased 37,088 shares during the quarter for an aggregate cost of $237.2 million. Shares outstanding declined to 2.64 million from 2.86 million a year earlier, helping offset part of the impact of lower net income on per-share earnings.

NVR’s Zacks Rank & A Few Construction ReleasesNVR currently has a Zacks Rank #5 (Strong Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

PulteGroup, Inc. (PHM - Free Report) reported third-quarter 2026 earnings of $2.53 per share, missing the Zacks Consensus Estimate of $2.63 by 3.8%. Earnings declined 14.5% from $2.96 per share in the year-ago quarter.

PulteGroup’s total revenues of $3.97 billion fell short of the consensus mark of $4.13 billion by 3.9% and decreased 9.8% year over year. Results reflected lower home-closing volumes, softer average selling prices and margin pressure amid affordability challenges, rising mortgage rates and inflation. Net new orders declined year over year, while backlog increased in both units and dollar value.

Lennar Corporation (LEN - Free Report) reported weaker-than-expected third-quarter fiscal 2026 (ended Aug. 31) results. Adjusted earnings of $1.23 per share missed the Zacks Consensus Estimate of $1.29 by 4.7% and fell 38.5% from $2.00 a year ago.

Lennar’s total revenues of $8.05 billion missed the consensus estimate of $8.33 billion by 3.4% and declined 8.6% year over year. Lower deliveries and home prices weighed on results amid affordability pressure. Inventory turn stood at 2.4 times.

United Rentals, Inc. (URI - Free Report) reported third-quarter 2026 results, with adjusted earnings per share and total revenues beating the Zacks Consensus Estimate and increasing year over year. URI’s adjusted earnings of $15.55 per share topped the Zacks Consensus Estimate of $13.83 by 12.4% and grew 32.9% year over year from $11.70. United Rentals’ total revenues rose 15.7% year over year to $4.89 billion and surpassed the consensus estimate of $4.69 billion by 4.3%.

Management raised its revenue outlook to $18-$18.2 billion from $17.5-$17.8 billion. Adjusted EBITDA is now projected at $8.3-$8.4 billion compared with $7.98-$8.13 billion previously.

The market expects Imperial Oil (IMO - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on October 30, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis oil and gas and petroleum products company is expected to post quarterly earnings of $3.43 per share in its upcoming report, which represents a year-over-year change of +118.5%.

Revenues are expected to be $15.44 billion, up 76.4% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 12% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Imperial Oil?For Imperial Oil, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that Imperial Oil will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Imperial Oil would post earnings of $2.99 per share when it actually produced earnings of $3.27, delivering a surprise of +9.36%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Imperial Oil doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company’s Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational, allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with progressive multiple sclerosis (MS). The data represent the first reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS and were presented in a late-breaking oral session at MSToronto2026, the 10th Joint Meeting of the Americas and European Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), being held October 21–23, 2026, in Toronto, Canada.

Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “These initial azer-cel results are particularly encouraging given that all patients entered the study with progressive disability despite prior treatment with high-efficacy therapies, including anti-CD20 treatment. The safety findings to date, together with evidence of B-cell depletion in both the blood and cerebrospinal fluid, demonstrate biological activity at doses that appear tolerable, while stable or improved disability scores in most subjects provide a potential signal of clinical activity. Of particular interest, five of the 18 evaluable patients experienced improvements in disability scores, including three patients with improvements of two or more points on the EDSS scale, an encouraging early finding in a disease where even slowing progression can represent an important therapeutic advance.”

Mr. Weiss continued, “While these results remain preliminary, we believe an off-the-shelf CAR T-cell therapy has the potential to offer a meaningful new treatment option for patients with progressive MS, where substantial unmet need remains. We look forward to continuing dose escalation and evaluating longer-term outcomes, and we are grateful to the patients, their families, and the clinical teams who are making this research possible.”

TG PRESENTATION:

Late-Breaking Oral Presentation: First Clinical Evaluation of an Allogeneic CD19-Directed CAR T-Cell Therapy in Progressive Multiple Sclerosis: Initial Results from the Phase 1 TG-Azercel-101 Study

The presentation includes data from 26 participants with progressive MS treated across six azer-cel dose levels, ranging from 30 million to 500 million CAR T-cells, following bendamustine lymphodepletion. All participants had experienced progression independent of relapse activity (PIRA) within the prior 12 months despite high-efficacy disease-modifying therapy, and all had previously received anti-CD20 therapy. The median baseline EDSS score was 6.0, reflecting substantial disability, with patients typically requiring assistance to walk even relatively short distances. As of the September 3, 2026 data cutoff, median follow-up was 4.9 months, with a range of 0.1 to 15.0 months.

Presentation Highlights:

Azer-cel demonstrated an encouraging initial safety profile in 26 participants, with no dose-limiting toxicities or high-grade CAR T associated toxicities observed across dose levels including no Grade ≥3 cytokine release syndrome (CRS), Grade ≥2 immune effector cell-associated neurotoxicity syndrome (ICANS), graft-versus-host disease, immune effector cell-associated hemophagocytic syndrome (IEC-HS) and no Grade ≥3 infections.Despite documented progression prior to enrollment, EDSS scores were stable or improved in 89% of evaluable participants at Day 90 (16/18) and 88% at Day 180 (7/8). Three participants achieved EDSS improvements of at least 2.0 points at Day 90, including one with a 4.0-point improvement.At Day 90, most evaluable participants demonstrated stable or improved walking performance (94%; 16/17), upper extremity function (94%; 17/18) and cognitive processing speed (78%; 14/18), with no gadolinium-enhancing T1 lesions or new or enlarging T2 lesions observed in any of the 22 participants evaluable by MRI.Peripheral blood B-cell counts were depleted to below 10 cells/µL in 96% of participants (25/26), and cerebrospinal fluid (CSF) samples from 21 participants showed a median reduction in CD19-positive B-cell events of 52.3% at Day 10. B-cell reconstitution was observed as early as Day 42 and favored transitional and naïve populations.These initial findings are from an ongoing, open-label Phase 1 study and are limited by the small number of participants and short follow-up. Dose escalation and longer-term follow-up are ongoing.

The full data presentation is also available on the Publications page of the Company’s website at https://www.tgtherapeutics.com/publications/.

ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IV
BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses.

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in several countries outside of the U.S. for the treatment of adult patients with RMS with active disease defined by clinical or imaging features.

A list of authorized specialty distributors can be found at www.briumvi.com.

IMPORTANT SAFETY INFORMATION
Contraindications: BRIUMVI is contraindicated in patients with:

Active Hepatitis B Virus infectionA history of life-threatening infusion reaction to BRIUMVIWARNINGS AND PRECAUTIONS

Infusion Reactions: BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence within 24 hours of the first infusion. 0.6% of BRIUMVI-treated patients experienced infusion reactions that were serious, some requiring hospitalization.

Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.

Infections: Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was 56% compared to 54% in teriflunomide-treated patients. The rate of serious infections was 5% compared to 3% respectively. There were 3 infection-related deaths in BRIUMVI-treated patients. The most common infections in BRIUMVI-treated patients included upper respiratory tract infection (45%) and urinary tract infection (10%). Delay BRIUMVI administration in patients with an active infection until the infection is resolved.

Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI.

Hepatitis B Virus (HBV) Reactivation:HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HB surface antigen (HBsAg) and anti-HB tests. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment.

Progressive Multifocal Leukoencephalopathy (PML):PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. JCV infection resulting in PML has been observed in patients treated with anti-CD20 antibodies, including BRIUMVI, and other MS therapies.

If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.

MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis.

If PML is confirmed, treatment with BRIUMVI should be discontinued.

Vaccinations:Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines, at least 4 weeks and, whenever possible, at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion.

Vaccination of Infants Born to Mothers Treated with BRIUMVI During Pregnancy:In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted.

Fetal Risk: Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose.

Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in 0.6% of BRIUMVI-treated patients compared to none of the patients treated with teriflunomide in RMS clinical trials. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy, until B-cell repletion. Consider discontinuing BRIUMVI therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.

Liver Injury: Clinically significant liver injury, without findings of viral hepatitis, has been reported in the postmarketing setting in patients treated with anti-CD20 B-cell depleting therapies approved for the treatment of MS, including BRIUMVI. Signs of liver injury, including markedly elevated serum hepatic enzymes with elevated total bilirubin, have occurred from weeks to months after administration.

Patients treated with BRIUMVI found to have an alanine aminotransaminase (ALT) or aspartate aminotransferase (AST) greater than 3x the upper limit of normal (ULN) with serum total bilirubin greater than 2x ULN are potentially at risk for severe drug-induced liver injury.

Obtain liver function tests prior to initiating treatment with BRIUMVI, and monitor for signs and symptoms of any hepatic injury during treatment. Measure serum aminotransferases, alkaline phosphatase, and bilirubin levels promptly in patients who report symptoms that may indicate liver injury, including new or worsening fatigue, anorexia, nausea, vomiting, right upper abdominal discomfort, dark urine, or jaundice. If liver injury is present and an alternative etiology is not identified, discontinue BRIUMVI.

Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least 10%) were infusion reactions and upper respiratory tract infections.

Physicians, pharmacists, or other healthcare professionals with questions about BRIUMVI should visit www.briumvi.com.

The full Summary of Product Characteristics approved in the European Union (EU) for BRIUMVI can be found here: Briumvi | European Medicines Agency (europa.eu).

ABOUT BRIUMVI PATIENT SUPPORT in the U.S.
BRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. More information about the BRIUMVI Patient Support program can be accessed at www.briumvipatientsupport.com.

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by several foreign nations for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

Cautionary Statement
This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below.

Such forward looking statements include but are not limited to statements regarding the potential safety, efficacy, durability of response and therapeutic benefits of azercabtagene zapreleucel (azer-cel) in progressive multiple sclerosis; its potential to provide an off-the-shelf treatment option; the interpretation and potential implications of the preliminary clinical findings described; and the Company’s plans for continued dose escalation, longer-term follow-up and further clinical development of azer-cel. Forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

These risks and uncertainties include, without limitation: the preliminary nature of the results from this ongoing, open-label Phase 1 study, which involves a small number of participants, multiple dose levels, limited follow-up and no concurrent control group; the possibility that reported results may change as additional participants are treated, follow-up increases and data are collected, reviewed and analyzed; the risk that observed stabilization or improvements in disability and other clinical measures may not be attributable to azer-cel, may not persist or may not be replicated in additional participants or subsequent studies; the risk that changes in B-cell populations or other biomarkers may not translate into clinical benefit; the potential for serious or previously unobserved adverse events associated with azer-cel, lymphodepleting treatment or their combination to emerge with additional treatment or longer follow-up; and the fact that the absence of certain adverse events in a limited population does not establish safety.

Additional risks include delays or difficulties in enrollment, dose escalation, manufacturing, supply, study conduct or data analysis; reliance on third parties for clinical development and manufacturing; the possibility that regulators may require additional studies, longer follow-up or changes to the development program; the Company’s ability to obtain adequate funding and maintain the rights and resources necessary to advance development; and the risk that azer-cel may not obtain regulatory approval or become commercially available. Azer-cel is investigational, and its safety and efficacy have not been established.

Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261023597209/en/

Booz Allen Hamilton Holding Corporation (BAH) Q2 2027 Earnings Call October 23, 2026 8:00 AM EDT

Company Participants

Dustin Darensbourg - Director & Head of Investor Relations
Horacio Rozanski - CEO & Chair
Kristine Anderson - COO & President
Troy Lahr - Executive VP & CFO

Conference Call Participants

Tobey Sommer - Truist Securities, Inc., Research Division
Gautam Khanna - TD Cowen, Research Division
Louie Dipalma - William Blair & Company L.L.C., Research Division
John Godyn - Citigroup Inc., Research Division
Sheila Kahyaoglu - Jefferies LLC, Research Division
Gavin Parsons - UBS Investment Bank, Research Division
Matthew Akers - BNP Paribas, Research Division
Scott Mikus - Melius Research LLC
Seth Seifman - JPMorgan Chase & Co, Research Division
Noah Poponak - Goldman Sachs Group, Inc., Research Division
Jonathan Siegmann - Stifel, Nicolaus & Company, Incorporated, Research Division

Presentation

Operator

Good morning. Thank you for standing by, and welcome to Booz Allen Hamilton's earnings call covering second quarter fiscal year 2027 results. [Operator Instructions] I would now like to turn the call over to the Head of Investor Relations, Dustin Darensbourg.

Dustin Darensbourg
Director & Head of Investor Relations

Thanks, Carmen. Good morning, and thank you for joining us for Booz Allen's Second Quarter Fiscal Year 2027 Earnings Call. We hope you've had an opportunity to read the press release we issued earlier this morning. We have also provided presentation slides on our website and are now on Slide 2. With me today to talk about our business and financial results are Horacio Rozanski, our Chairman and Chief Executive Officer; Kristine Martin Anderson, President and Chief Operating Officer; and Troy Lahr, Executive Vice President and Chief Financial Officer.

As shown in the disclaimer on Slide 3, some of the items we will discuss this morning are forward-looking and may relate to future events and as such, involve known and unknown risks, uncertainties and other factors

Wall Street analysts forecast that GE Vernova (GEV - Free Report) will report quarterly earnings of $4.03 per share in its upcoming release, pointing to a year-over-year increase of 145.7%. It is anticipated that revenues will amount to $12.1 billion, exhibiting an increase of 21.4% compared to the year-ago quarter.

The consensus EPS estimate for the quarter has undergone a downward revision of 3.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

In light of this perspective, let's dive into the average estimates of certain GE Vernova metrics that are commonly tracked and forecasted by Wall Street analysts.

Analysts' assessment points toward 'Revenues- Wind' reaching $2.33 billion. The estimate points to a change of -11.9% from the year-ago quarter.

The average prediction of analysts places 'Revenues- Wind- Services' at $466.86 million. The estimate points to a change of +5.2% from the year-ago quarter.

Analysts predict that the 'Revenues- Wind- Equipment' will reach $1.87 billion. The estimate indicates a year-over-year change of -15%.

Analysts expect 'Revenues- Power' to come in at $5.74 billion. The estimate suggests a change of +18.6% year over year.

It is projected by analysts that the 'Revenues- Electrification' will reach $4.01 billion. The estimate indicates a change of +54.1% from the prior-year quarter.

Analysts forecast 'Revenues- Power- Services' to reach $3.48 billion. The estimate indicates a year-over-year change of +12.8%.

The consensus estimate for 'Revenues- Power- Equipment' stands at $2.26 billion. The estimate points to a change of +35.2% from the year-ago quarter.

The consensus among analysts is that 'Revenues- Electrification- Equipment' will reach $3.20 billion. The estimate indicates a change of +58.6% from the prior-year quarter.

According to the collective judgment of analysts, 'Revenues- Wind- Offshore Wind' should come in at $257.78 million. The estimate indicates a change of +32.2% from the prior-year quarter.

The combined assessment of analysts suggests that 'Revenues- Wind- Onshore Wind' will likely reach $2.08 billion. The estimate points to a change of -13.6% from the year-ago quarter.

The collective assessment of analysts points to an estimated 'Revenues- Power- Gas Power' of $4.84 billion. The estimate points to a change of +23.4% from the year-ago quarter.

Based on the collective assessment of analysts, 'Power - Gas Turbine Gigawatts' should arrive at N/A. Compared to the current estimate, the company reported N/A in the same quarter of the previous year.

View all Key Company Metrics for GE Vernova here>>>

Shares of GE Vernova have experienced a change of -13.4% in the past month compared to the -1.2% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), GEV is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.82% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Petrobras (PBR - Free Report) Headquartered in Rio de Janeiro, Petroleo Brasileiro S.A., or Petrobras S.A., is the largest integrated energy firm in Brazil and one of the largest in Latin America. The company’s activities include: exploration, exploitation and production of oil from reservoir wells, shale and other rocks, as well as refining, processing, trading and transportation of oil and oil products, natural gas and other fluid hydrocarbons, in addition to other energy-related activities. The company operates in three main segments:

PBR is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Momentum investors should take note of this Oils-Energy stock. PBR has a Momentum Style Score of A, and shares are up 22.9% over the past four weeks.

For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $1.18 to $5.99 per share. PBR boasts an average earnings surprise of +3%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, PBR should be on investors' short list.

Rigetti Computing, Inc. (RGTI - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this company have returned -30.4%, compared to the Zacks S&P 500 composite's -1.2% change. During this period, the Zacks Internet - Software industry, which Rigetti Computing falls in, has lost 5.8%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Rigetti Computing is expected to post a loss of $0.05 per share, indicating a change of -66.7% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

For the current fiscal year, the consensus earnings estimate of -$0.19 points to a change of +70.3% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $0.19 indicates a change of +2.1% from what Rigetti Computing is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Rigetti Computing is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Rigetti Computing, the consensus sales estimate for the current quarter of $3.89 million indicates a year-over-year change of +99.6%. For the current and next fiscal years, $24.55 million and $71.21 million estimates indicate +246.4% and +190% changes, respectively.

Last Reported Results and Surprise HistoryRigetti Computing reported revenues of $5.14 million in the last reported quarter, representing a year-over-year change of +185.6%. EPS of -$0.05 for the same period compares with -$0.05 a year ago.

Compared to the Zacks Consensus Estimate of $4.91 million, the reported revenues represent a surprise of +4.58%. The EPS surprise was -66.67%.

Over the last four quarters, Rigetti Computing surpassed consensus EPS estimates three times. The company topped consensus revenue estimates two times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Rigetti Computing is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Rigetti Computing. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

LOS ANGELES, Oct. 23, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors of upcoming lead plaintiff deadlines in securities class action lawsuits filed on behalf of shareholders of Gildan Activewear Inc., D-Wave Quantum, Inc., and Bank Of America Corporation. Investors who wish to seek appointment as lead plaintiff must file a motion by the deadlines listed below.

If you lost money on these investments, contact The Law Offices of Frank R. Cruz about these class actions to learn about your legal rights, by calling 310-914-5007 or emailing [email protected].

Gildan Activewear Inc. (NYSE: GIL)

Class period: February 19, 2025 through June 15, 2026Lead plaintiff motion deadline: December 14, 2026Case: Cortez v. Gildan Activewear Inc. et al., filed in the U.S. District Court Northern District of New York According to the Gildan Activewear Inc. complaint, throughout the class period the defendants made false and/or misleading statements and/or failed to disclose that: (i) Gildan did not have adequate internal controls; and (ii) Gildan used channel stuffing to create an appearance of revenue.

If you are a Gildan Activewear Inc. shareholder who suffered a loss, click here to participate.

D-Wave Quantum, Inc. (NASDAQ: QBTS)

Class period: February 26, 2026 through August 25, 2026Lead plaintiff motion deadline: December 15, 2026Case: Fessler v. D-Wave Quantum, Inc. et al., filed in the U.S. District Court California Northern District According to the D-Wave Quantum, Inc. complaint, throughout the class period the defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants materially overstated D-Wave’s business and financial prospects; and (ii) the foregoing was reasonably likely to negatively impact the Company’s business and reputation.

If you are a D-Wave Quantum, Inc. shareholder who suffered a loss, click here to participate.

Bank Of America Corporation (NYSE: BAC)

Class period: August 1, 2025 through October 13, 2026Lead plaintiff motion deadline: December 15, 2026Case: New England Teamsters Pension Fund v. Bank of America Corporation et al., filed in the U.S. District Court Southern District of New York According to the Bank Of America Corporation complaint, throughout the class period the defendants made false and/or misleading statements and/or failed to disclose that: (i) systemic weaknesses in BANA's BSA/AML program caused it to fail to properly monitor trillions of dollars in transactions and to miss, delay, or file inaccurate or incomplete suspicious activity reports involving billions of dollars in suspicious activity; (ii) internal reports had documented BANA's BSA/AML deficiencies for years, yet BANA had not adequately remedied them after the 2024 Consent Order; (iii) BANA also had deficiencies in its sanctions compliance program and processed transactions later identified as apparent violations of multiple sanctions programs; and (iv) fixing these deficiencies required significant additional compliance resources and exposed BANA to substantial penalties and costs.

If you are a Bank Of America Corporation shareholder who suffered a loss, click here to participate.

What should investors in these cases do now?

Investors need not take any action at this time to be class members in these cases. Investors may retain counsel of their choice or take no action and remain absent class members. No class has been certified yet in any of these cases.

For more information about these class actions or your rights, contact Frank R. Cruz of The Law Offices of Frank R. Cruz at 310-914-5007, by email at [email protected], or visit the firm's case page.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

About The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz investigates and prosecutes securities fraud and corporate malfeasance class actions. With nearly 20 years of litigation experience, the firm focuses on complex securities class actions and gives each client personal, one-on-one attention throughout the legal process.

Prior results do not guarantee a similar outcome.

Contact

Frank R. Cruz

The Law Offices of Frank R. Cruz

Los Angeles, CA

Email: [email protected]

Telephone: 310-914-5007

www.frankcruzlaw.com

Follow The Law Offices of Frank R. Cruz for updates on Twitter: twitter.com/FRC_LAW

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Rogers Communications (NYSE:RCI) increased free cash flow by 65% to C$1.37 billion in the third quarter as lower spending helped strengthen its balance sheet.

The Canadian telecoms and media group reaffirmed its 2026 outlook for service revenue, adjusted earnings before interest, tax, depreciation and amortisation (EBITDA), capital expenditure and free cash flow.

Revenue rose 2% to C$5.44 billion in the three months to 30 September, while adjusted EBITDA increased 1% to C$2.54 billion.

Capital expenditure fell 46% to C$524 million, reducing capital intensity, the proportion of revenue spent on capital investment, to 9.6% from 18% a year earlier.

Rogers generated C$3.13 billion of free cash flow in the first nine months of 2026, up 34% year on year, while cash from operating activities increased 6% to C$4.67 billion.

The company is targeting further debt reduction by the first half of 2027 through the planned sale of a minority interest in its sports, media and entertainment assets.

Rogers completed the C$4.35 billion acquisition of the remaining 25% stake in Maple Leaf Sports & Entertainment (MLSE) on October 1, giving it full ownership of the business.

MLSE owns the Toronto Maple Leafs ice hockey team, Toronto Raptors basketball team and Toronto FC football club, alongside Scotiabank (TSX:BNS) Arena and other sports and entertainment assets.

Rogers intends to use proceeds from the planned minority stake sale to repay debt, with its debt leverage ratio standing at 3.7 times adjusted EBITDA at the end of September.

The group’s wireless business delivered a 1% increase in adjusted EBITDA, while its margin expanded to 68% as higher equipment margins offset pressure on service revenue.

Wireless service revenue fell 1% to C$2.03 billion, reflecting competitive pricing pressure and lower fee income following regulatory changes, while mobile phone net additions weakened.

Cable service revenue remained broadly stable at C$1.98 billion, although adjusted EBITDA increased 1% as operational efficiency measures lifted the segment’s margin to 58.6%.

Media revenue rose 9% to C$821 million, supported by stronger sports revenue and higher subscriptions for the Warner Bros Discovery channel portfolio, while adjusted EBITDA increased 12% to C$84 million.

Net income fell 91% to C$495 million, largely reflecting a C$5 billion non-cash gain recognised in the prior-year quarter when Rogers revalued its existing MLSE investment following an earlier transaction.

Adjusted net income declined 3% to C$701 million as higher financing costs partly offset the improvement in adjusted EBITDA.

3 Low P/E Stocks: Separating Multibaggers From a Value TrapRogers Communication NYSE: RCI reported third-quarter 2026 service revenue and adjusted EBITDA growth of 1% each as the Canadian telecom company emphasized cost discipline, lower capital spending and the value of its sports and media assets amid slower wireless market activity.

President and Chief Executive Officer Tony Staffieri said the company generated more than CAD 1.3 billion in free cash flow during the quarter, while capital expenditures fell 46%. Rogers’ debt leverage ratio improved to 3.7 times, down from 3.8 times in the preceding quarter.

Get Rogers Communication alerts:

Rogers Communication Stock Should Be Launching Higher “Against the backdrop of lower market activity, we continued to deliver on our commitments and our long-term strategy,” Staffieri said. He added that Rogers posted wireless and cable adjusted EBITDA margins of 68% and 59%, respectively.

Wireless results reflect regulatory and market pressures
Wireless service revenue declined 1% from a year earlier, primarily due to a Canadian Radio-television and Telecommunications Commission decision that prohibited certain fees beginning in mid-June, according to Chief Financial Officer Glenn Brandt. Mobile phone average revenue per user, or ARPU, fell 2.6% to CAD 55.22.

Brandt said that excluding the CRTC decision, Rogers would have reported modest positive wireless service revenue growth and a sequential improvement in its ARPU decline. He said the company is seeking other ways to offset or reduce costs that had previously been covered by the affected fees.

Rogers added 17,000 total mobile phone customers during the quarter, including 6,000 postpaid additions. Staffieri said the company chose to focus on premium plans and customer value propositions rather than pursue volume through deeper price discounts during the back-to-school season.

Postpaid mobile phone churn rose four basis points year over year to 1.03%. Brandt attributed the increase largely to pricing actions taken early in the quarter and said the company viewed the impact as temporary. He also noted that incoming ARPU for customers added during the third quarter and into October was up 8% from a year earlier.

Management estimated that industry mobile net additions were down roughly 30% to 40% year over year in the third quarter. Staffieri said penetration growth appeared to have softened to roughly 1.5% to 2%, compared with a more traditional range of 2% to 2.5%, while population growth was essentially flat.

Cable growth continues as capital spending declines
Rogers’ cable service revenue grew for the sixth consecutive quarter, though reported growth was modest due in part to the December 2025 sale of customer-facing data centers. Excluding that sale, cable service revenue increased 1% organically, while cable adjusted EBITDA also rose 1%.

The cable adjusted EBITDA margin expanded 40 basis points to 59%. Brandt said the improvement reflected operational scale, continued cost-efficiency efforts, integration of practices from the Shaw operations and greater use of offshore resources for some call-center work.

Retail internet net additions totaled 10,000, reflecting lower market activity and Rogers’ focus on premium service rather than price-led customer acquisition. During the question-and-answer session, Brandt declined to break out revenue contributions between broadband and video, satellite and home-phone products, saying the company views its different categories of residential customers as important to overall performance.

Capital expenditures fell to CAD 524 million, producing a capital intensity ratio of 9.6% in the quarter. Brandt said lower spending partly reflected the sale of projects that were no longer priorities, which also removes future capital requirements. He said Rogers’ CAD 2.5 billion to CAD 2.7 billion capital-expenditure outlook for 2026 should indicate expectations for the near term, though the company did not formally provide 2027 guidance.

Staffieri said the lower capital envelope would not impair network performance or growth prospects. He cited ongoing network investments, rural connectivity opportunities and potential enterprise and Internet-of-Things applications from the company’s satellite partnership with SpaceX.

Sports and media strategy advances
Rogers completed its acquisition of the remaining 25% stake in Maple Leaf Sports & Entertainment on Oct. 1. Staffieri said the transaction gives Rogers full ownership of a collection of sports, entertainment and media assets that includes professional teams, Sportsnet and live-event venues.

The company plans to consolidate its sports, media and entertainment assets and sell a minority interest to third-party investors, targeting a closing in the first half of 2027. Brandt said proceeds from such a sale would be used to reduce debt.

Management pointed to rising sports franchise values, as well as the company’s media and live-entertainment operations, as evidence of the portfolio’s potential value. Staffieri said Rogers’ partnership with Live Nation to bring the Backstreet Boys to Canada for a 12-show residency next year at Rogers Centre illustrates how the company can combine venues, entertainment and customer offerings.

Rogers Sports & Media revenue rose 9% in the quarter, while adjusted EBITDA increased 12% to CAD 84 million. The Toronto Blue Jays helped support the results, with more than 3.3 million fans attending games during the regular season and average attendance reaching 97% of capacity, according to Staffieri.

Cash flow outlook reaffirmed
Free cash flow totaled approximately CAD 1.4 billion in the quarter, up 65% from a year earlier, aided by lower capital expenditures and lower cash taxes. Through the first nine months of 2026, free cash flow exceeded CAD 3.1 billion, up 34% year over year.

Rogers ended the quarter with CAD 8.3 billion in available liquidity, including CAD 3 billion of cash and cash equivalents and CAD 5 billion available under bank and other credit facilities. The figure did not include an additional CAD 5 billion of bilateral bank credit facilities arranged for the MLSE purchase.

Net income declined by about CAD 5.3 billion from the prior-year quarter, which included a CAD 5 billion non-cash gain related to Rogers’ original MLSE interest following its July 2025 purchase of BCE’s interest in the sports organization.

The company reaffirmed its 2026 outlook for 3% to 5% total service revenue growth, 1% to 3% adjusted EBITDA growth, capital expenditures of CAD 2.5 billion to CAD 2.7 billion, and free cash flow of CAD 4.1 billion to CAD 4.3 billion.

About Rogers Communication (NYSE:RCI)Rogers Communications Inc is a Canadian communications and media company serving consumers, businesses and public-sector organizations across Canada. Its telecommunications operations provide wireless voice and data services, broadband internet, television, home phone and related connectivity products. The company also offers enterprise networking, cybersecurity, cloud and other information technology services.

Rogers operates a portfolio of media and sports properties, including Sportsnet, Citytv and OMNI Television, along with radio stations, digital platforms and publishing operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Rogers Communication Right Now?Before you consider Rogers Communication, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rogers Communication wasn't on the list.

While Rogers Communication currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

The market expects Capri Holdings (CPRI - Free Report) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on October 30, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis luxury retailer is expected to post quarterly earnings of $0.21 per share in its upcoming report, which represents a year-over-year change of +800%.

Revenues are expected to be $781.27 million, down 8.7% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Capri Holdings?For Capri Holdings, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +4.76%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination indicates that Capri Holdings will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Capri Holdings would post earnings of $0.4 per share when it actually produced earnings of $0.67, delivering a surprise of +67.50%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Capri Holdings appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsBoot Barn (BOOT - Free Report) , another stock in the Zacks Retail - Apparel and Shoes industry, is expected to report earnings per share of $1.63 for the quarter ended September 2026. This estimate points to a year-over-year change of +19%. Revenues for the quarter are expected to be $581.15 million, up 15% from the year-ago quarter.

The consensus EPS estimate for Boot Barn has remained unchanged over the last 30 days. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +0.49%.

When combined with a Zacks Rank of #2 (Buy), this Earnings ESP indicates that Boot Barn will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Cava Group (CAVA - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this Mediterranean restaurant chain have returned +2.2%, compared to the Zacks S&P 500 composite's -1.2% change. During this period, the Zacks Retail - Restaurants industry, which Cava falls in, has gained 3.6%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

Cava is expected to post earnings of $0.12 per share for the current quarter, representing no change from the year-ago quarter. Over the last 30 days, the Zacks Consensus Estimate has changed +3.3%.

For the current fiscal year, the consensus earnings estimate of $0.55 points to a change of +1.9% from the prior year. Over the last 30 days, this estimate has changed +0.3%.

For the next fiscal year, the consensus earnings estimate of $0.74 indicates a change of +34.2% from what Cava is expected to report a year ago. Over the past month, the estimate has changed -2.5%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Cava.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Cava, the consensus sales estimate for the current quarter of $357.44 million indicates a year-over-year change of +22.3%. For the current and next fiscal years, $1.51 billion and $1.79 billion estimates indicate +27.7% and +18.9% changes, respectively.

Last Reported Results and Surprise HistoryCava reported revenues of $368.44 million in the last reported quarter, representing a year-over-year change of +31.3%. EPS of $0.19 for the same period compares with $0.16 a year ago.

Compared to the Zacks Consensus Estimate of $353.31 million, the reported revenues represent a surprise of +4.28%. The EPS surprise was +5.56%.

Over the last four quarters, Cava surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Cava is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Cava. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

SanDisk has shed a third of its value in a month even as its business posts record numbers and locks in nearly $94 billion in signed customer contracts. One top analyst sees a near-triple from here, but the bull case…

SanDisk (NASDAQ:SNDK | SNDK Price Prediction) currently trades at $1,260.93, while Wall Street’s average price target is $2,173. That gap works out to 72.3% implied upside.

SanDisk is the NAND flash pure-play that was spun out in February 2025. AI datacenter storage demand has made it one of the market’s biggest winners. Fiscal fourth-quarter revenue reached $8.96 billion, up 371.6% year over year, and non-GAAP EPS of $39.25 beat the $33.28 estimate.

The gap stands out because the stock has pulled back just as the business looks strongest. Melius Research analyst Ben Reitzes holds a Street-high target of $3,600, which implies 185.5% upside. That is close to triple the current price.

China Memory Fears and Profit-Taking Drag SanDisk Down 33% in a Month The biggest blow came from reports that China’s ChangXin Memory Technologies had made progress on next-generation DRAM and server-grade DDR5 chips. That news triggered selling across memory stocks. SanDisk has lost 33.18% over the past month. It fell 8.51% in the latest session alone and now sits 46.4% below its 52-week high of $2,354.39.

SanDisk makes NAND, a separate product from DRAM, so ChangXin’s progress is a less direct threat. Other pressures piled on anyway: profit-taking after the 2026 rally, rising Treasury yields and concerns about debt-funded AI infrastructure spending. The company’s own numbers remain strong. SanDisk has beaten EPS estimates five straight quarters.

Analysts See $93.9 Billion in Contracts the Market Is Discounting The bull case rests on SanDisk’s multi-year customer agreements, which the company calls NBMs. CFO Luis Visoso said signed NBMs carry total expected revenue of “a minimum of $93.9 billion, assuming floor pricing.” Those contracts are expected to cover more than 50% of bits in fiscal 2027 and approximately two-thirds in fiscal 2028, and they are backed by $16.5 billion in financial guarantees.

Melius builds its $3,600 target on three pillars: demand for High-Bandwidth Flash, tight NAND pricing and free cash flow strong enough to support up to $100 billion in buybacks over three years. Other desks sit close behind, with Bernstein at $3,000 and Cantor Fitzgerald at $2,900. The board has already added $14 billion in buyback authorization.

Recent updates have been positive. Mizuho maintained Outperform and raised its target to $2,050, and Rosenblatt initiated at Buy with a $2,400 target. The next test is the upcoming earnings report. Guidance calls for revenue of $10.30 billion to $10.80 billion and EPS of $44.00 to $46.00.

Price targets are opinions, though. The $3,600 call assumes pricing stays strong in a NAND market that management expects to grow 3x year over year in 2026.

Every Storage Name Sold Off, and SanDisk Fell Hardest The whole storage group fell together. Over the past month, SanDisk dropped more than any of its peers.

Micron Technology (NASDAQ:MU) is down 20.09% over the past month. It trades at $856.49 versus a $1,560.57 target and offers 82.2% implied upside. Nine analysts rate it Strong Buy, 36 Buy, three Hold and one Strong Sell. That is more consensus upside than SanDisk.

Western Digital (NASDAQ:WDC), SanDisk’s former parent, has fallen 25.23% in a month. At $354.19 versus a $654 target, the implied upside is 84.6%, with four Strong Buy, 17 Buy and five Hold ratings.

Seagate Technology (NASDAQ:STX) is down 30.49% in a month. It trades at $642.14 versus a $1,116.58 target and offers 73.9% upside, which is similar to SanDisk.

On consensus targets, Western Digital has the most upside in the group, and SanDisk has the least. SanDisk’s case rests heavily on its outlier targets.

A 431% Year Still Survives the Slide At $1,260.93, SanDisk would need to rise 72.3% to reach the $2,173 consensus. Here is how the 25 covering analysts rate the stock:

Strong Buy: 4 Buy: 17 Hold: 3 Strong Sell: 1 Even after the selloff, the stock is up 431.19% year to date, while the S&P 500 has gained 12.03%. Over the past month, SanDisk fell 33.18% while the index slipped 0.5%. The forward P/E is about 8.

Signed Revenue Tilts Me Bullish Before Earnings My view on SanDisk becomes more constructive if the coming earnings report hits guidance and NBM coverage keeps growing. That would show signed pricing holding up in a falling market. My view becomes cautious if NAND pricing rolls over or AI capex budgets shrink. Floor-price contracts protect revenue, yet margins near 84.6% leave a long way to fall.

I lean bullish. A forward multiple near 8 with $93.9 billion in signed floor revenue reflects much of the bad news. Still, I’d treat the $3,600 target as a ceiling, and the consensus is the more realistic mark to measure against.

Contact [email protected] for any questions or corrections.

For the quarter ended September 2026, Flagstar Bank (FLG - Free Report) reported revenue of $530 million, up 2.1% over the same period last year. EPS came in at $0.01, compared to -$0.07 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $537.38 million, representing a surprise of -1.37%. The company delivered an EPS surprise of -83.33%, with the consensus EPS estimate being $0.06.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Flagstar Bank performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Interest Margin: 2.2% versus the seven-analyst average estimate of 2.2%.Efficiency Ratio: 87.6% compared to the 82.3% average estimate based on six analysts.Net charge-offs to average loans: 0.5% versus 0.4% estimated by six analysts on average.Average Balances - Interest earning assets: $84.25 billion compared to the $83.59 billion average estimate based on six analysts.Book value per common share (GAAP): $17.82 versus the five-analyst average estimate of $18.71.Total Non-performing loans: $2.82 billion compared to the $2.61 billion average estimate based on two analysts.Total risk-based capital ratio: 15.7% versus the two-analyst average estimate of 16.2%.Tier 1 risk-based capital ratio: 13.2% versus the two-analyst average estimate of 13.7%.Total Nonperforming Assets: $2.83 billion versus the two-analyst average estimate of $2.62 billion.Leverage Capital Ratio: 9.3% versus 9.6% estimated by two analysts on average.Net Interest Income: $460 million versus the seven-analyst average estimate of $459.39 million.Total non-interest income (loss): $70 million compared to the $77.05 million average estimate based on seven analysts.View all Key Company Metrics for Flagstar Bank here>>>

Shares of Flagstar Bank have returned -7.7% over the past month versus the Zacks S&P 500 composite's -1.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Modine (MOD - Free Report) .

Modine currently has an average brokerage recommendation (ABR) of 1.33, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 12 brokerage firms. An ABR of 1.33 approximates between Strong Buy and Buy.

Of the 12 recommendations that derive the current ABR, 11 are Strong Buy, representing 91.7% of all recommendations.

Brokerage Recommendation Trends for MOD

Check price target & stock forecast for Modine here>>>

While the ABR calls for buying Modine, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Is MOD Worth Investing In?Looking at the earnings estimate revisions for Modine, the Zacks Consensus Estimate for the current year has declined 8.2% over the past month to $7.02.

Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #5 (Strong Sell) for Modine. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, it could be wise to take the Buy-equivalent ABR for Modine with a grain of salt.

4.99K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Space Exploration Technologies Corp., aka SpaceX, is well positioned for massive growth, targeting $100B ARR and up to 3 GW compute capacity by year-end, finishing very strongly for 2026. SPCX's compute rental business and Starlink's 13.6M subscribers underpin robust near-term economics and fund aggressive terrestrial and AI expansion. Management is securing $40B in debt financing to support a multi-year AI infrastructure buildout and potentially hitting 23 GW in power capacity by FY2027.

SpaceX is reportedly in talks to secure a minimum of 80,000 cell sites across the US, a move that would solidify the rocket and satellite giant's path toward building a fourth nationwide wireless carrier. Ruhell Amin reports on Bloomberg Television.

Toll Brothers (TOL - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this home builder have returned +3.8% over the past month versus the Zacks S&P 500 composite's -1.2% change. The Zacks Building Products - Home Builders industry, to which Toll Brothers belongs, has lost 0.6% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Toll Brothers is expected to post earnings of $4.89 per share, indicating a change of +6.8% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.1% over the last 30 days.

The consensus earnings estimate of $12.8 for the current fiscal year indicates a year-over-year change of -5.1%. This estimate has changed -0.1% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $13.78 indicates a change of +7.7% from what Toll Brothers is expected to report a year ago. Over the past month, the estimate has changed -1%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Toll Brothers.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For Toll Brothers, the consensus sales estimate for the current quarter of $3.51 billion indicates a year-over-year change of +2.4%. For the current and next fiscal years, $10.84 billion and $10.92 billion estimates indicate -1.2% and +0.8% changes, respectively.

Last Reported Results and Surprise HistoryToll Brothers reported revenues of $2.66 billion in the last reported quarter, representing a year-over-year change of -9.7%. EPS of $2.97 for the same period compares with $3.73 a year ago.

Compared to the Zacks Consensus Estimate of $2.6 billion, the reported revenues represent a surprise of +2.36%. The EPS surprise was +2.41%.

Over the last four quarters, Toll Brothers surpassed consensus EPS estimates three times. The company topped consensus revenue estimates each time over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Toll Brothers is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Toll Brothers. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Forvis Mazars Wealth Advisors LLC lifted its holdings in Apple Inc. (NASDAQ:AAPL – Free Report) by 5.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 195,668 shares of the iPhone maker’s stock after acquiring an additional 9,723 shares during the period. Apple accounts for about 1.1% of Forvis Mazars Wealth Advisors LLC’s portfolio, making the stock its 14th biggest holding. Forvis Mazars Wealth Advisors LLC’s holdings in Apple were worth $64,304,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. State Street Corp boosted its stake in Apple by 4.7% in the 2nd quarter. State Street Corp now owns 630,662,494 shares of the iPhone maker’s stock worth $182,897,769,000 after purchasing an additional 28,321,085 shares during the period. Berkshire Hathaway Inc purchased a new stake in Apple during the 2nd quarter valued at approximately $65,950,297,000. Bank of America Corp DE purchased a new stake in Apple during the 2nd quarter valued at approximately $36,986,090,000. Legal & General Group Plc bought a new stake in shares of Apple during the second quarter valued at approximately $30,443,242,000. Finally, Amundi raised its position in shares of Apple by 23.2% during the first quarter. Amundi now owns 73,082,616 shares of the iPhone maker’s stock valued at $18,547,637,000 after buying an additional 13,780,080 shares during the last quarter. Institutional investors own 67.73% of the company’s stock.

More Apple News Here are the key news stories impacting Apple this week:

Positive Sentiment: Strong iPhone Duo demand is the main catalyst. Preorders for the $1,999 foldable reportedly sold out quickly, with delivery dates extending into 2027. DigiTimes reported that Apple raised its 12-month shipment target by 44% to 14 million units, up from an initial 9.7 million. iPhone Duo preorder surge prompts Apple to raise shipment targets Positive Sentiment: The foldable launches Friday with supply constrained. Limited store inventory, combined with online backorders, could support near-term pricing power and signal meaningful demand for a new premium product category. Apple bets iPhone Duo can remake foldable market Positive Sentiment: Apple is increasingly viewed as an AI “safe haven.” Investors are favoring the company’s substantial cash generation and device-focused AI strategy over rivals committing enormous sums to centralized data centers. Berkshire Hathaway’s continued large Apple holding also reinforces the stock’s defensive appeal. Apple’s Cash Flow Machine Makes It Investors’ Favorite AI Hedge Positive Sentiment: Additional growth opportunities are emerging. Apple is expanding its smart-home ecosystem with Schneider Electric and has another product event scheduled for October 28, potentially providing further catalysts. Schneider Electric teams up with Apple on smart-home products Neutral Sentiment: Valuation remains the key debate. Apple’s approximately 40 times earnings multiple and $5 trillion valuation leave investors dependent on strong holiday sales, expanding margins and sustained product growth. Analysts remain divided, with some projecting another major growth phase while others see limited upside. Negative Sentiment: Loop Capital downgraded AAPL to Hold over valuation and concerns about iPhone shipment prospects, creating a counterweight to the upbeat foldable-phone reports. Apple slips as Loop Capital downgrades on iPhone shipment concerns Negative Sentiment: Insider selling and ETF outflows add modest pressure. SVP Jennifer Newstead sold 2,399 shares worth about $815,000, while reports also cited net ETF selling and additional insider transactions. These trades are relatively small compared with Apple’s size but may reinforce valuation concerns. Apple Stock Up 1.2% NASDAQ AAPL opened at $348.22 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.93 and a current ratio of 1.00. The company has a market capitalization of $5.08 trillion, a P/E ratio of 39.93, a P/E/G ratio of 2.72 and a beta of 1.07. Apple Inc. has a one year low of $243.42 and a one year high of $348.36. The stock has a 50 day moving average price of $328.91 and a 200-day moving average price of $309.07. Apple (NASDAQ:AAPL – Get Free Report) last posted its earnings results on Thursday, July 30th. The iPhone maker reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.89 by $0.13. Apple had a net margin of 27.62% and a return on equity of 135.46%. The firm had revenue of $109.42 billion during the quarter, compared to analyst estimates of $109.04 billion. During the same period last year, the firm posted $1.57 earnings per share. Apple’s revenue for the quarter was up 16.4% compared to the same quarter last year. As a group, equities analysts predict that Apple Inc. will post 8.75 EPS for the current fiscal year.

Apple Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Thursday, August 13th. Shareholders of record on Monday, August 10th were given a dividend of $0.27 per share. The ex-dividend date was Monday, August 10th. This represents a $1.08 annualized dividend and a yield of 0.3%. Apple’s dividend payout ratio (DPR) is 12.39%.

Insider Buying and Selling at Apple In other news, SVP Deirdre O’brien sold 46,389 shares of the business’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $333.42, for a total value of $15,467,020.38. Following the sale, the senior vice president directly owned 136,810 shares in the company, valued at $45,615,190.20. The trade was a 25.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Timothy D. Cook sold 191,753 shares of the company’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $332.96, for a total transaction of $63,846,078.88. Following the sale, the insider owned 3,264,168 shares in the company, valued at $1,086,837,377.28. This represents a 5.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 286,853 shares of company stock worth $95,477,342 over the last three months. 0.06% of the stock is owned by company insiders.

Wall Street Analyst Weigh In Several equities analysts have recently commented on AAPL shares. Citic Securities boosted their target price on shares of Apple from $300.00 to $349.00 in a report on Thursday, August 6th. China Renaissance cut shares of Apple from a “buy” rating to a “hold” rating and cut their target price for the company from $329.00 to $280.00 in a research note on Tuesday, August 4th. Morgan Stanley reiterated an “overweight” rating on shares of Apple in a report on Wednesday. Deutsche Bank Aktiengesellschaft downgraded shares of Apple from a “buy” rating to a “hold” rating in a report on Monday, August 17th. Finally, Raymond James Financial reiterated a “market perform” rating on shares of Apple in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Apple presently has an average rating of “Moderate Buy” and a consensus price target of $340.12.

Get Our Latest Research Report on AAPL

Apple Company Profile (Free Report)

Apple Inc designs, develops and sells consumer electronics, software and digital services. Its best-known products include the iPhone smartphone, Mac personal computers, iPad tablets, Apple Watch, AirPods and other accessories. The company also develops operating systems and applications that support its hardware ecosystem.

Apple’s services business includes the App Store, Apple Music, Apple TV, Apple Arcade, iCloud, Apple Pay and other subscription, payment and digital-content offerings.

Recommended Stories Five stocks we like better than Apple Is Texas Instruments Setting Up for Its Next Big Breakout? Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was Tesla’s Flying-Car Hype Hits an Earnings Reality Check

Receive News & Ratings for Apple Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apple and related companies with MarketBeat.com's FREE daily email newsletter.

Edge Wealth Management LLC trimmed its holdings in Apple Inc. (NASDAQ:AAPL – Free Report) by 1.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 163,487 shares of the iPhone maker’s stock after selling 1,861 shares during the period. Apple comprises approximately 7.9% of Edge Wealth Management LLC’s holdings, making the stock its 3rd largest holding. Edge Wealth Management LLC’s holdings in Apple were worth $55,002,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in AAPL. Avenir Tech Ltd acquired a new stake in Apple in the second quarter valued at $29,000. Longfellow Investment Management Co. LLC acquired a new position in Apple during the 2nd quarter worth $30,000. Ascentis Wealth Management LLC grew its holdings in Apple by 822.7% during the 2nd quarter. Ascentis Wealth Management LLC now owns 292,493 shares of the iPhone maker’s stock worth $85,000 after acquiring an additional 260,792 shares in the last quarter. Bamco Inc. NY acquired a new position in Apple during the 2nd quarter worth $118,000. Finally, Bard Associates Inc. bought a new stake in shares of Apple in the 2nd quarter worth about $161,000. 67.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades AAPL has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Apple in a research note on Thursday, October 1st. Weiss Ratings raised shares of Apple from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Yorkville Ives initiated coverage on Apple in a research note on Tuesday, October 6th. They issued an “outperform” rating and a $400.00 price target for the company. Loop Capital downgraded Apple from a “buy” rating to a “hold” rating and decreased their price target for the stock from $370.00 to $330.00 in a research note on Tuesday. Finally, Seaport Research Partners lowered Apple from a “buy” rating to a “neutral” rating in a report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $340.12.

Check Out Our Latest Stock Analysis on Apple Insider Activity In other Apple news, SVP Jennifer Newstead sold 2,399 shares of Apple stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $339.62, for a total value of $814,748.38. Following the completion of the transaction, the senior vice president directly owned 34,795 shares in the company, valued at $11,817,077.90. The trade was a 6.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Deirdre O’brien sold 46,389 shares of Apple stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $333.42, for a total value of $15,467,020.38. Following the completion of the transaction, the senior vice president owned 136,810 shares of the company’s stock, valued at approximately $45,615,190.20. The trade was a 25.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 286,853 shares of company stock valued at $95,477,342 over the last quarter. Corporate insiders own 0.06% of the company’s stock.

Apple Stock Performance Apple stock opened at $348.22 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.93. Apple Inc. has a 12 month low of $243.42 and a 12 month high of $348.36. The company has a fifty day moving average price of $328.91 and a two-hundred day moving average price of $309.07. The company has a market cap of $5.08 trillion, a PE ratio of 39.93, a P/E/G ratio of 2.72 and a beta of 1.07.

Apple (NASDAQ:AAPL – Get Free Report) last issued its earnings results on Thursday, July 30th. The iPhone maker reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.89 by $0.13. The company had revenue of $109.42 billion for the quarter, compared to analysts’ expectations of $109.04 billion. Apple had a net margin of 27.62% and a return on equity of 135.46%. The firm’s revenue was up 16.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.57 earnings per share. Research analysts expect that Apple Inc. will post 8.75 earnings per share for the current year.

Apple Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Thursday, August 13th. Investors of record on Monday, August 10th were given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, August 10th. Apple’s dividend payout ratio is currently 12.39%.

More Apple News Here are the key news stories impacting Apple this week:

Positive Sentiment: Strong iPhone Duo demand is the main catalyst. Preorders for the $1,999 foldable reportedly sold out quickly, with delivery dates extending into 2027. DigiTimes reported that Apple raised its 12-month shipment target by 44% to 14 million units, up from an initial 9.7 million. iPhone Duo preorder surge prompts Apple to raise shipment targets Positive Sentiment: The foldable launches Friday with supply constrained. Limited store inventory, combined with online backorders, could support near-term pricing power and signal meaningful demand for a new premium product category. Apple bets iPhone Duo can remake foldable market Positive Sentiment: Apple is increasingly viewed as an AI “safe haven.” Investors are favoring the company’s substantial cash generation and device-focused AI strategy over rivals committing enormous sums to centralized data centers. Berkshire Hathaway’s continued large Apple holding also reinforces the stock’s defensive appeal. Apple’s Cash Flow Machine Makes It Investors’ Favorite AI Hedge Positive Sentiment: Additional growth opportunities are emerging. Apple is expanding its smart-home ecosystem with Schneider Electric and has another product event scheduled for October 28, potentially providing further catalysts. Schneider Electric teams up with Apple on smart-home products Neutral Sentiment: Valuation remains the key debate. Apple’s approximately 40 times earnings multiple and $5 trillion valuation leave investors dependent on strong holiday sales, expanding margins and sustained product growth. Analysts remain divided, with some projecting another major growth phase while others see limited upside. Negative Sentiment: Loop Capital downgraded AAPL to Hold over valuation and concerns about iPhone shipment prospects, creating a counterweight to the upbeat foldable-phone reports. Apple slips as Loop Capital downgrades on iPhone shipment concerns Negative Sentiment: Insider selling and ETF outflows add modest pressure. SVP Jennifer Newstead sold 2,399 shares worth about $815,000, while reports also cited net ETF selling and additional insider transactions. These trades are relatively small compared with Apple’s size but may reinforce valuation concerns. About Apple (Free Report)

Apple Inc designs, develops and sells consumer electronics, software and digital services. Its best-known products include the iPhone smartphone, Mac personal computers, iPad tablets, Apple Watch, AirPods and other accessories. The company also develops operating systems and applications that support its hardware ecosystem.

Apple’s services business includes the App Store, Apple Music, Apple TV, Apple Arcade, iCloud, Apple Pay and other subscription, payment and digital-content offerings.

Recommended Stories Five stocks we like better than Apple Is Texas Instruments Setting Up for Its Next Big Breakout? Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was Tesla’s Flying-Car Hype Hits an Earnings Reality Check Want to see what other hedge funds are holding AAPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apple Inc. (NASDAQ:AAPL – Free Report).

Receive News & Ratings for Apple Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apple and related companies with MarketBeat.com's FREE daily email newsletter.

Courier Capital LLC cut its position in shares of Apple Inc. (NASDAQ:AAPL – Free Report) by 72.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 67,838 shares of the iPhone maker’s stock after selling 179,694 shares during the quarter. Apple accounts for 4.2% of Courier Capital LLC’s portfolio, making the stock its 4th largest position. Courier Capital LLC’s holdings in Apple were worth $22,213,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Avenir Tech Ltd acquired a new position in Apple during the second quarter worth about $29,000. Longfellow Investment Management Co. LLC bought a new stake in Apple in the second quarter worth about $30,000. Ascentis Wealth Management LLC lifted its holdings in Apple by 822.7% in the 2nd quarter. Ascentis Wealth Management LLC now owns 292,493 shares of the iPhone maker’s stock valued at $85,000 after acquiring an additional 260,792 shares during the last quarter. Bamco Inc. NY acquired a new stake in Apple in the 2nd quarter valued at about $118,000. Finally, Bard Associates Inc. acquired a new stake in Apple in the 2nd quarter valued at about $161,000. 67.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In AAPL has been the subject of several research reports. Robert W. Baird raised their price objective on shares of Apple from $310.00 to $330.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Oppenheimer reiterated a “market perform” rating on shares of Apple in a report on Thursday, September 10th. Raymond James Financial reissued a “market perform” rating on shares of Apple in a research note on Friday, July 31st. Wells Fargo & Company restated an “overweight” rating and set a $350.00 target price (up from $310.00) on shares of Apple in a report on Friday, July 31st. Finally, Barclays restated an “underweight” rating and set a $245.00 target price (down from $253.00) on shares of Apple in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $340.12.

Check Out Our Latest Stock Report on Apple More Apple News Here are the key news stories impacting Apple this week:

Positive Sentiment: Strong iPhone Duo demand is the main catalyst. Preorders for the $1,999 foldable reportedly sold out quickly, with delivery dates extending into 2027. DigiTimes reported that Apple raised its 12-month shipment target by 44% to 14 million units, up from an initial 9.7 million. iPhone Duo preorder surge prompts Apple to raise shipment targets Positive Sentiment: The foldable launches Friday with supply constrained. Limited store inventory, combined with online backorders, could support near-term pricing power and signal meaningful demand for a new premium product category. Apple bets iPhone Duo can remake foldable market Positive Sentiment: Apple is increasingly viewed as an AI “safe haven.” Investors are favoring the company’s substantial cash generation and device-focused AI strategy over rivals committing enormous sums to centralized data centers. Berkshire Hathaway’s continued large Apple holding also reinforces the stock’s defensive appeal. Apple’s Cash Flow Machine Makes It Investors’ Favorite AI Hedge Positive Sentiment: Additional growth opportunities are emerging. Apple is expanding its smart-home ecosystem with Schneider Electric and has another product event scheduled for October 28, potentially providing further catalysts. Schneider Electric teams up with Apple on smart-home products Neutral Sentiment: Valuation remains the key debate. Apple’s approximately 40 times earnings multiple and $5 trillion valuation leave investors dependent on strong holiday sales, expanding margins and sustained product growth. Analysts remain divided, with some projecting another major growth phase while others see limited upside. Negative Sentiment: Loop Capital downgraded AAPL to Hold over valuation and concerns about iPhone shipment prospects, creating a counterweight to the upbeat foldable-phone reports. Apple slips as Loop Capital downgrades on iPhone shipment concerns Negative Sentiment: Insider selling and ETF outflows add modest pressure. SVP Jennifer Newstead sold 2,399 shares worth about $815,000, while reports also cited net ETF selling and additional insider transactions. These trades are relatively small compared with Apple’s size but may reinforce valuation concerns. Apple Trading Up 1.2% Shares of AAPL opened at $348.22 on Friday. The business’s 50-day moving average price is $328.91 and its 200 day moving average price is $309.07. The company has a current ratio of 1.00, a quick ratio of 0.93 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $5.08 trillion, a P/E ratio of 39.93, a P/E/G ratio of 2.72 and a beta of 1.07. Apple Inc. has a 1-year low of $243.42 and a 1-year high of $348.36.

Apple (NASDAQ:AAPL – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The iPhone maker reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.89 by $0.13. Apple had a net margin of 27.62% and a return on equity of 135.46%. The company had revenue of $109.42 billion during the quarter, compared to analyst estimates of $109.04 billion. During the same period in the prior year, the firm earned $1.57 earnings per share. The business’s quarterly revenue was up 16.4% on a year-over-year basis. Analysts expect that Apple Inc. will post 8.75 earnings per share for the current year.

Apple Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Thursday, August 13th. Stockholders of record on Monday, August 10th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, August 10th. Apple’s dividend payout ratio (DPR) is 12.39%.

Insider Buying and Selling at Apple In other news, SVP Jennifer Newstead sold 2,399 shares of the business’s stock in a transaction that occurred on Tuesday, October 20th. The shares were sold at an average price of $339.62, for a total transaction of $814,748.38. Following the sale, the senior vice president owned 34,795 shares in the company, valued at $11,817,077.90. The trade was a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kevan Parekh sold 1,392 shares of the company’s stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of $345.05, for a total transaction of $480,309.60. Following the completion of the sale, the chief financial officer owned 17,539 shares of the company’s stock, valued at approximately $6,051,831.95. This trade represents a 7.35% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 286,853 shares of company stock valued at $95,477,342 over the last three months. 0.06% of the stock is owned by insiders.

About Apple (Free Report)

Apple Inc designs, develops and sells consumer electronics, software and digital services. Its best-known products include the iPhone smartphone, Mac personal computers, iPad tablets, Apple Watch, AirPods and other accessories. The company also develops operating systems and applications that support its hardware ecosystem.

Apple’s services business includes the App Store, Apple Music, Apple TV, Apple Arcade, iCloud, Apple Pay and other subscription, payment and digital-content offerings.

Recommended Stories Five stocks we like better than Apple Is Texas Instruments Setting Up for Its Next Big Breakout? Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was Tesla’s Flying-Car Hype Hits an Earnings Reality Check

Receive News & Ratings for Apple Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apple and related companies with MarketBeat.com's FREE daily email newsletter.